TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11412155
Drug: Nefopam 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 0.12 mg.kg‐1
Study: 2842144
Drug: Flumazenil (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (3.0 mg)
Study: 3543247
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) recombinant interferon (IFN) alfa‐2b at a dosage of 2 X 10(6) IU/m2 three times weekly.
Study: 3543247
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) recombinant interferon (IFN) alfa‐2b at a dosage of 30 X 10(6) IU/m2 for five consecutive days every 3 weeks.
Study: 3543247
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis of patients with prior nephrectomy, no prior treatment, and lack of bone metastases.
Study: 3543247
Drug: Both SC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SC and IV routes of administration.
Study: 24114306
Drug: Delayed antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotics group
Study: 22097104
Drug: Assertiveness Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertiveness Music Therapy
Study: 15473523
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (2 mg/kg/day)
Study: 19032560
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg/ml
Study: 9496328
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of 10,000 IU recombinant human LH
Study: 9496328
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of 10,000 IU recombinant human LH
Study: 9496328
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of 10,000 IU recombinant human LH
Study: 7993988
Drug: Enteric-coated tablet
Normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablet (EC)
Study: 7993988
Drug: Plain capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain capsule (PC)
Study: 2789363
Drug: Ponsinomycin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsinomycin 400 mg
Study: 2789363
Drug: Ponsinomycin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsinomycin 800 mg
Study: 2789363
Drug: Ponsinomycin 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsinomycin 1200 mg
Study: 29127558
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone (4 mg)
Study: 29127558
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone (4 mg) vs Intravenous dexamethasone (4 mg)
Study: 29127558
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg vs 4 mg dexamethasone
Study: 28259777
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide (25 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Study: 28259777
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (300 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Study: 26497961
Drug: No rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rate control drug (baseline)
Study: 17323614
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg or Simvastatin 40 mg
Study: 17323614
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of statin + 200 mg micronized fenofibrate
Study: 17323614
Drug: Statin +
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statin + 3.6 g n-3 polyene fatty acids (PUFA n-3)
Study: 14664413
Drug: Climex (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climex (5 chewable tablets daily between meals)
Study: 10760307
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy plus hematopoietic stem cells
Study: 8622391
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg once daily)
Study: 29720370
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum 25(OH)D concentrations (<25 nmol/L)
Study: 27454372
Drug: Higher intercepts
Normalized name: INTERCEPTOR
DrugBank: Milbemycin oxime (DB11531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher intercepts during treatment
Study: 11731725
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with bilateral electrode placement at 50% above the titrated seizure threshold
Study: 9142008
Drug: AS-013 (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-013 (prostaglandin E1 prodrug) administered by intravenous injection 5 d/wk for 4 weeks
Study: 7956270
Drug: Both sequences
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sequences of surgical treatments
Study: 3230146
Drug: A-56234 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-56234 at 20 mg
Study: 3230146
Drug: A-56234 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-56234 at 40 mg
Study: 3230146
Drug: A-56234 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-56234 at 60 mg
Study: 3230146
Drug: A-56234 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-56234 at 80 mg
Study: 12046816
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol monotherapy
Study: 30005743
Drug: Atorvastatin (lipophilic)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (lipophilic)
Study: 18297975
Drug: Pharmacotherapy trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy trials
Study: 18297975
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of psychotherapy and pharmacotherapy trials
Study: 16802855
Drug: Oxycodone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.2 mg/kg buccally
Study: 16802855
Drug: Oxycodone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.2 mg/kg sublingually
Study: 14711140
Drug: Intravenous alefacept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alefacept
Study: 10836009
Drug: Curative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative treatment for hepatic malignancies
Study: 10836009
Drug: Investigational therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational therapies for hepatic malignancies
Study: 1565349
Drug: Ibuprofen, 600
Normalized name: Ibuprofen, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 600 mg
Study: 6323378
Drug: Oral mecillinam
Normalized name: mecillinam
DrugBank: Amdinocillin (DB01163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mecillinam
Study: 29525763
Drug: Pilates twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates twice a week (PG2)
Study: 29525763
Drug: Pilates twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates twice a week (PG2) vs Pilates once a week (PG1)
Study: 27154357
Drug: LY +
Normalized name: Thrifty White One Daily + Iron Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY + SUN (LY2510924 20 mg SC daily + Sunitinib 50 mg PO daily for 4 weeks followed by 2 weeks off)
Study: 27154357
Drug: SUN (Sunitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUN (Sunitinib 50 mg PO daily for 4 weeks followed by 2 weeks off)
Study: 11808937
Drug: Initial phlebotomy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial phlebotomy to reduce serum ferritin levels to 10 ng/ml or less followed by maintenance phlebotomy for 5 years
Study: 10411862
Drug: Lovastatin +
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin + warfarin combination
Study: 8635022
Drug: Lipiodol-epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol-epirubicin (75 mg/m2)
Study: 2073669
Drug: Lovastatin (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (final average dose 70.5 mg/day)
Study: 6845976
Drug: THIP (4,5,6,7‐tetrahydroisoxazolo(5,4‐c)pyridin‐3‐ol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THIP (4,5,6,7‐tetrahydroisoxazolo(5,4‐c)pyridin‐3‐ol) at doses of 15 to 120 mg/day
Study: 6845976
Drug: THIP (submaximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THIP (submaximal doses)
Study: 29562558
Drug: Conventional dysphagia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dysphagia treatment
Study: 27627193
Drug: Omarigliptin 10
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 10 mg
Study: 24724807
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid (5 mg/day)
Study: 22998754
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (25 μg per day as cholecalciferol)
Study: 22998754
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 μg per day as lactose)
Study: 21051846
Drug: Gynoflor® (lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynoflor® (lyophilized lactobacilli and 0.03 mg estriol)
Study: 21051846
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg vaginal suppositories)
Study: 17417917
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 20 mg daily plus Clarithromycin (Cla) 500 mg b.d. and Amoxicillin (Am) 1,000 mg b.d. for 7 days
Study: 17417917
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 20 mg daily plus Clarithromycin (Cla) 500 mg b.d. and Amoxicillin (Am) 1,000 mg b.d. for 14 days
Study: 15244246
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide, methotrexate, or 5-fluorouracil (CMF)
Study: 11031403
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of antibiotics and a chemical matrixectomy simultaneously (group 1)
Study: 11031403
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for 1 week and then a matrixectomy (group 2)
Study: 2869001
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg once a day
Study: 2869001
Drug: oxprenolol 80
Normalized name: oxprenolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxprenolol 80 mg twice a day
Study: 2869001
Drug: nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nadolol 80 mg once a day
Study: 29378991
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 100 mg (Group BT)
Study: 29378991
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 8 mg (Group BD)
Study: 21227563
Drug: 6 min
Normalized name: garlic 6 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 min of monthly practice on a voice advisory manikin
Study: 18497677
Drug: Single-dose rATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rATG (6 mg/kg)
Study: 18497677
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses rATG (1.5 mg/kg every other day for 4 days)
Study: 10960528
Drug: AS-24 (hypotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-24 (hypotonic storage solution)
Study: 10960528
Drug: AS-3 (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-3 (control storage solution)
Study: 8977678
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using a portable desktop lamp with 300 W xenon short arc discharge source and topical 5-aminolaevulinic acid (5-ALA) applied 4 hours before irradiation, 125 J/cm2 at a fluence rate of 70 mW/cm2.
Study: 1309410
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% ophthalmic solution, administered twice daily
Study: 30179056
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin (40 mg m‐2) with bowel sparing IMRT (50 Gy/25#/5 wks)
Study: 30179056
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow dose volume constraints
Study: 26531052
Drug: Mydrane (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mydrane (200 μL of a combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1%)
Study: 26531052
Drug: Topical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regimen (one drop each of tropicamide 0.5% and phenylephrine 10% repeated three times)
Study: 24781517
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg nicotine oral soluble film
Study: 19535699
Drug: Helium inhalation
Normalized name: helium Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium inhalation at an end-tidal concentration of 50 vol% during ischemia-reperfusion
Study: 19535699
Drug: Helium inhalation
Normalized name: helium Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium inhalation at an end-tidal concentration of 50 vol%
Study: 19535699
Drug: Control (absence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (absence of helium inhalation)
Study: 9435773
Drug: Anti-epileptic medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-epileptic medication added to existing drug regime
Study: 31439831
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral cannabidiol
Study: 29263660
Drug: Long-acting β‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β‐2 agonist (LABA)
Study: 26388284
Drug: Low-sodium PD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium PD solution (125 mmol/L sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity 338-491 mOsm/L)
Study: 26388284
Drug: Standard-sodium PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-sodium PD solution (134 mmol/L sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity 356-509 mOsm/L)
Study: 21719695
Drug: Testosterone supplementation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone supplementation with testosterone buccal adhesive patches 2 × 30 mg/d for 8 months
Study: 21719695
Drug: Intraplaque verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraplaque verapamil injections associated with testosterone administration
Study: 21719695
Drug: Intraplaque verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraplaque verapamil injections associated with a placebo
Study: 10349044
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment with akathisia (n = 15)
Study: 10349044
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment without akathisia (n = 18)
Study: 10349044
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (both groups)
Study: 7493423
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (5 mg) with hypoxic mixture (FiO2 = 12%)
Study: 7493423
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (5 mg) with normoxic mixture
Study: 1674394
Drug: Epanolol 100
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol 100 mg
Study: 1674394
Drug: Epanolol 200
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol 200 mg
Study: 1674394
Drug: Epanolol 300
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol 300 mg
Study: 1674394
Drug: Epanolol (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol (pooled data of 3 doses)
Study: 6765503
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of vitamin B6 and magnesium
Study: 29985978
Drug: Ivermectin-based mass
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin-based mass drug administration (MDA)
Study: 29985978
Drug: Ivermectin-based MDA
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin-based MDA co-administered with azithromycin
Study: 29985978
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment arm (azithromycin with ivermectin)
Study: 20224451
Drug: CBEX drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBEX drink (containing total 2 g of carnosine and anserine)
Study: 1564022
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dose of methylphenidate
Study: 15526500
Drug: Mix 25
Normalized name: Fluclomix 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix 25 (insulin lispro low mixture)
Study: 10933350
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 g twice daily)
Study: 8725472
Drug: Granisetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (2 mg oral dose)
Study: 30007343
Drug: Mediterranean-like dietary
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean-like dietary pattern with vitamin D3 (10 µg/d) supplements
Study: 8659419
Drug: Helical CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helical CT (HC) acquisition after contrast injection at 6 ml/sec
Study: 8659419
Drug: Dynamic sequential
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic sequential CT (DS) acquisition after contrast injection at 2 ml/sec
Study: 8659419
Drug: Dynamic sequential
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic sequential CT (DS)
Study: 1573555
Drug: Neomycin complexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin complexed on xanthan, administered in a unique daily dose
Study: 1573555
Drug: Ampicillin or
Normalized name: ampicillin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin or furazolidone, administered for 5-10 days or longer
Study: 3887877
Drug: Sotalol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (160 mg once daily, increased to 320 mg, 480 mg, and 640 mg if necessary)
Study: 28791808
Drug: Sonography guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonography guided injection of hyaluronic acid
Study: 28791808
Drug: Blind injection
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injection of hyaluronic acid
Study: 28791808
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Sonography guided and Blind injection)
Study: 18242357
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg intravenously and/or 500 mg orally twice daily for 10 days
Study: 7006476
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of isoniazid, rifampin, and ethambutol for 8 weeks, followed by daily for 18 weeks
Study: 7006476
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly administration of isoniazid, rifampin, and ethambutol during the continuation phase
Study: 7006476
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly administration of isoniazid, rifampin, and ethambutol during the continuation phase
Study: 7006476
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly administration of isoniazid and rifampin during the continuation phase
Study: 31337958
Drug: NXT15906F6-250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXT15906F6-250 mg
Study: 31337958
Drug: NXT15906F6-400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXT15906F6-400 mg